ClinicalTrials.gg
CompletedNCT00856622Updated Feb 21, 2021

A Study Demonstrating The Effect Of Latanoprost In Combination With Timolol, Latanoprost Alone And Timolol Alone On Eye Pressure In Open Angle Glaucoma Or Ocular Hypertension In Patients

A Phase 3 interventional study of i. Fixed combination of latanoprost 0.005% and timolol 0.5% and timolol 0.5% ophthalmic solution in Ocular Hypertension, Glaucoma and Open-angle Glaucoma, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 37 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-21.

Primary conditionGlaucoma, Open-AngleRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
436
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Glaucoma, Open-Angle by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Glaucoma, Open-Angle · Viatris Inc..

Enrollment
4th of 12
436 · median 288
Started
1997
the only one that year
Phase 3
8 of 15
none open now
Registered
14th of 15
by date

Among the 15 studies in Glaucoma, Open-Angle by Viatris Inc., this one is the 4th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 1997, is one of 8 in phase 3, and was the 14th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 15 studies in Glaucoma, Open-Angle by Viatris Inc. is open now. The open studies under Glaucoma, Open-Angle, anywhere →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Glaucoma, Open-Angle by Viatris Inc. as a file.
02

Study summary

The purpose of this study is to demonstrate that fixed combination of latanoprost and timolol (PhXA41) has better IOP lowering effect than the individual monotherapies.

03

Conditions studied

  • Ocular Hypertension
  • Glaucoma
  • Open-angle Glaucoma

Browse trials for

Keywords

  • open-angle glaucoma ocular hypertension glaucoma
04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 436 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.
  • Patients currently on IOP reducing therapy: IOP greater than or equal to 25mmHg (two IOP determinations at pre-study separated by at least one hour) OR Patients without IOP reducing therapy: IOP greater than or equal to 30mmHg (two IOP determinations at pre-study separated by at least one hour).

Exclusion criteria

Exclusion Criteria:

  • History of acute angle closure or closed/barely open anterior chamber angle.
  • Current use of contact lenses.
  • Ocular surgery or argon laser trabeculoplasty () within three months prior to pre-study visit.
  • Ocular inflammation/infection occurring within three months prior to pre-study visit.
  • to benzalkonium chloride or to any other component of the study drug solutions.
  • Other abnormal ocular condition or symptom preventing the patient from entering the study, according to the investigator's judgement.
  • Cardiac failure, sinus bradycardia, second and third degree of atrioventricular block. (The routines for prescribing topical B-blocking agents will be followed.
  • Bronchial asthma, history of bronchial asthma or . (The routines for prescribing topical B-blocking agents will be followed).
  • Pregnancy
  • Women of who has not used adequate methods during the last three months.
  • Inability to adhere to treatment/visit plan.
  • Have participated in any other clinical study within one month prior to pre-study visit.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
436 participants (actual)

Study arms

  • Experimental
    Fixed combination of latanoprost 0.005% and timolol 0.5%

    Drug: i. Fixed combination of latanoprost 0.005% and timolol 0.5%

  • Active comparator
    timolol 0.5% ophthalmic solution

    one drop in the morning and evening

    Drug: timolol 0.5% ophthalmic solution

  • Active comparator
    latanoprost 0.005% ophthalmic solution

    placebo in the morning and latanoprost .005% in the evening

    Drug: latanoprost 0.005% ophthalmic solution

Interventions

  • Drugi. Fixed combination of latanoprost 0.005% and timolol 0.5%

    one drop in the morning and placebo in the evening

    Also known as: xalacom, xalcom

  • one drop in the morning and evening

    Also known as: timoptic

  • placebo in the morning and latanoprost .005% in the evening

    Also known as: xalatan

07

What researchers measure

Primary outcomes

  1. To demonstrate that the fixed combination of latanoprost and timolol has a better IOP-reducing effect than the individual monotherapies.

    Time frame: 6 months

Secondary outcomes

  1. To examine, within treatment groups, the diurnal IOP reducing effect from baseline for all treatments at Week 26

    Time frame: 6 Months

  2. To compare the diurnal IOP reducing effect from baseline between the monotherapies latanoprost and timolol at Week 26

    Time frame: 6 Months

  3. To compare the number of treatment failures and patients withdrawn due to uncontrolled IOP from baseline to Week 26 between treatment groups

    Time frame: 6 Months

  4. To compare the proportion of patients reaching pre-specified (15, 18, and 21 mmHg) target diurnal IOPs between the treatment groups at Week 26

    Time frame: 6 Months

  5. To describe the IOP development from baseline to Week 26 for all treatment groups

    Time frame: 6 Months

  6. To compared the IOP reducing effect from baseline to Week 26 of the monotherapies with the IOP reducing effect from Week 26 to Week 52 of the fixed combination

    Time frame: 6 Months

  7. To examine, within the fixed combination treatment group, the diurnal IOP reducing effect from baseline to Week 26 and Week 52

    Time frame: 6 Months

  8. To follow the safety variables throughout the study periods.

    Time frame: 6 Months

08

Study locations

37 sites
  • Pfizer Investigational Site
    Aachen, Germany
  • Pfizer Investigational Site
    Aalen, Germany
  • Pfizer Investigational Site
    Ahaus, 48683, Germany
  • Pfizer Investigational Site
    Alzey, 55232, Germany
  • Pfizer Investigational Site
    Aschaffenburg, 63739, Germany
  • Pfizer Investigational Site
    Bad Abbach, 93077, Germany
  • Pfizer Investigational Site
    Berlin, 13088, Germany
  • Pfizer Investigational Site
    Coesfeld, 48653, Germany
  • Pfizer Investigational Site
    Dillingen, 89407, Germany
  • Pfizer Investigational Site
    Eitorf, 53783, Germany
  • Pfizer Investigational Site
    Erlangen, 91052, Germany
  • Pfizer Investigational Site
    Essen, 45147, Germany
  • Pfizer Investigational Site
    Freiburg, 79106, Germany
  • Pfizer Investigational Site
    Freising, 85354, Germany
  • Pfizer Investigational Site
    Fulda, Germany
  • Pfizer Investigational Site
    Greifswald, 17489, Germany
  • Pfizer Investigational Site
    Gummersbach, 51643, Germany
  • Pfizer Investigational Site
    Hannover, Germany
  • Pfizer Investigational Site
    Hirschaid, 96114, Germany
  • Pfizer Investigational Site
    Iserlohn, 58638, Germany
  • Pfizer Investigational Site
    Koblenz, 56068, Germany
  • Pfizer Investigational Site
    Leonberg, 71229, Germany
  • Pfizer Investigational Site
    Leverkusen, 51373, Germany
  • Pfizer Investigational Site
    Mainz, 55116, Germany
  • Pfizer Investigational Site
    Mainz, 55124, Germany
  • Pfizer Investigational Site
    Mainz, 55131, Germany
  • Pfizer Investigational Site
    Muenchen, 80336, Germany
  • Pfizer Investigational Site
    Muenchen, 81925, Germany
  • Pfizer Investigational Site
    Mülheim, 45481, Germany
  • Pfizer Investigational Site
    Münster, 48165, Germany
  • Pfizer Investigational Site
    Offenbach, 63065, Germany
  • Pfizer Investigational Site
    Osnabrueck, 49076, Germany
  • Pfizer Investigational Site
    Parsberg, 92331, Germany
  • Pfizer Investigational Site
    Siegburg, 53721, Germany
  • Pfizer Investigational Site
    Sulzbach, 66280, Germany
  • Pfizer Investigational Site
    Trier, 54290, Germany
  • Pfizer Investigational Site
    Weiden, 92637, Germany
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 1997, a primary completion of Jun 1999 and a completion of Jun 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2009
First posted
Mar 6, 2009
Start
Aug 1997
Primary completionActual
Jun 1999
CompletionActual
Jun 1999
Last update
Feb 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00856622
Responsible party
Sponsor
First posted
Mar 6, 2009
Start date
Aug 1997
Primary completion
Jun 1999
Completion
Jun 1999
Last update
Feb 21, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion